Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-22T19:00:17.634Z Has data issue: false hasContentIssue false

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

Published online by Cambridge University Press:  16 April 2020

C.U. Correll*
Affiliation:
The Zucker Hillside Hospital, Psychiatry Research, 75-59 263rd Street, Glen Oaks, NY11004, USA
*
Correspondence. E-mail address: [email protected]
Get access

Abstract

Determinants of antipsychotic selection and response include parameters of the primary disorder, psychiatric and physical comorbidities, past treatment effects, patient preferences, availability and acceptability of different treatments and formulations, as well as expected efficacy and safety. In the absence of consistent and sufficiently large efficacy differences among antipsychotics (except for clozapine in refractory patients), and in view of a greater focus on physical health, functional outcomes and quality of life, relatively more predictable differences in adverse events have become an important management consideration. Treatments are often selected because of a relatively lower propensity for extrapyramidal and sexual side effects, sedation, and, especially, the reduced development of cardiometabolic risk states and disorders. In this context, differences in receptor binding affinity, intrinsic activity and in the half life of antipsychotics are crucial to adopt adequate dosing and switching strategies. Dopamine rebound phenomena can occur when the level of dopamine blockade is not kept relatively constant during the switch process. This can happen when the new antipsychotic is underdosed or not fully absorbed, the switch is too abrupt from an antipsychotic with a short half life to one with a much longer half life, or when a dopamine antagonist is switched too fast to an antipsychotic with markedly less dopamine affinity or to a partial dopamine agonist. Intra-switch destabilization can also occur when changing too quickly from antipsychotics with strong histaminergic and/or cholinergic blockade to ones with lower affinity to these receptors. Overlapping “plateau” switch strategies and transient co-treatment with calming medications, such as benzodiazepines, have emerged as potential solutions to these rebound phenomena that can complicate the early switch period. To optimize outcomes, antipsychotic treatment should be pharmacologically informed and measurement based, combining both acute and long-term management goals and balancing efficacy and adverse effect considerations.

Type
Research Article
Copyright
Copyright © 2010 Elsevier Masson SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barnes, T.R.E.Paton, C.Cavanagh, M.-R.Hancock, E.Taylor, D.M.An UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bull 2007; 33: 13971403CrossRefGoogle ScholarPubMed
Buckley, P.F.Correll, C.U.Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69(Suppl 1): 417Google ScholarPubMed
Burris, K.D.Molski, T.F.Xu, C.Ryan, E.Tottori, K.Kikuchi, T., et al.Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381389CrossRefGoogle ScholarPubMed
Citrome, L.Jaffe, A.Levine, J.Datapoints:, The ups and downs of dosing second-generation antipsychotics. Psychiatr Serv 2007; 58(1): 11CrossRefGoogle ScholarPubMed
Correll, C.U.Leucht, S.Kane, J.M.Lower risk for tardive dyskinesia associated with second-generation antipsychotics:a systematic review of 1-year studies. Am J Psychiatry 2004; 161(3): 414425CrossRefGoogle ScholarPubMed
Correll, C.U.Sheridan, E.M.DelBello, M.P.Antipsychotic and Mood Stabilizer Efficacy and Tolerability in Adult and Pediatric Patients with Bipolar I Mania: A Comparative Analysis of Acute, Randomized, Placebo-Controlled Trials. Bipolar Disorders 2010; 12: 116141CrossRefGoogle ScholarPubMed
Correll, C.U.Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 920CrossRefGoogle ScholarPubMed
Correll, C.U.Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007; 12(10 Suppl 17): 1220, 35CrossRefGoogle ScholarPubMed
Correll, C.U.Real-life dosing with second-generation antipsychotics. J Clin Psychiatry 2005; 66: 16101611CrossRefGoogle ScholarPubMed
Correll, C.U.Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006; 67: 160161CrossRefGoogle ScholarPubMed
Fischer-Barnicol, D.Lanquillon, S.Haen, E.Zofel, P.Koch, H.J.Dose, M., et al.Working Group ‘Drugs in Psychiatry’. Typical and atypical antipsychotics— the misleading dichotomy. Results from the Working Group ‘Drugs in Psychiatry’ (AGATE). Neuropsychobiology 2008; 57(1–2): 8087CrossRefGoogle Scholar
Fountoulakis, K.N.Vieta, E.Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11(7): 9991029. Epub 2008 Aug 28.CrossRefGoogle Scholar
Gao, K.Sheehan, D.V.Calabrese, J.R.Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009; 9(8): 11471158CrossRefGoogle ScholarPubMed
Kahn, R.S.Fleischhacker, W.W.Boter, H.Davidson, M.Vergouwe, Y.Keet, I.P., et al.EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:an open randomised clinical trial. Lancet 2008; 371(9618): 10851097CrossRefGoogle ScholarPubMed
Kapur, S.Zipursky, R.Jones, C.Shammi, C.S.Remington, G.Seeman, P.A positron emission tomography study of quetiapine in schizophrenia:a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6): 553559CrossRefGoogle ScholarPubMed
Leucht, S.Arbter, D.Engel, R.R.Kissling, W.Davis, J.M.How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14(4): 429447CrossRefGoogle ScholarPubMed
Leucht, S.Barnes, T.R.Kissling, W.Engel, R.R.Correll, C.Kane, J.M.Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 12091222CrossRefGoogle ScholarPubMed
Leucht, S.Corves, C.Arbter, D.Engel, R.R.Li, C.Davis, J.M.Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 3141CrossRefGoogle ScholarPubMed
Leucht, S.Komossa, K.Rummel-Kluge, C.Corves, C.Hunger, H.Schmid, F., et al.A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166(2): 152163CrossRefGoogle ScholarPubMed
Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O., et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 12091223CrossRefGoogle ScholarPubMed
McDougle, C.J.Stigler, K.A.Erickson, C.A.Posey, D.J.Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008; 69(Suppl 4): 1520Google ScholarPubMed
Morrato, E.H.Druss, B.Hartung, D.M.Valuck, R.J.Allen, R.Campagna, E., et al.Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67(1): 1724CrossRefGoogle ScholarPubMed
Nelson, J.C.Papakostas, G.I.Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166(9): 980991CrossRefGoogle ScholarPubMed
Owen, R.Sikich, L.Marcus, R.N.Corey-Lisle, P.Manos, G.McQuade, R.D., et al.Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124(6): 15331540CrossRefGoogle ScholarPubMed
Pappadopulos, E.Woolston, S.Chait, A.Perkins, M.Connor, D.F.Jensen, P.S.Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006; 15(1): 2739Google ScholarPubMed
Remington, G.Chue, P.Stip, E.Kopala, L.Girard, T.Christensen, B.The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005; 76(2–3): 267272CrossRefGoogle ScholarPubMed
Roth, B. NIH Psychoactive Drug Screening Program; http://pdsp.med.unc.edu, last accessed March 3, 2010.Google Scholar
Scherk, H.Pajonk, F.G.Leucht, S.Second-generation antipsychotic agents in the treatment of acute mania:a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64(4): 442455CrossRefGoogle Scholar
Schooler, N.Rabinowitz, J.Davidson, M.Emsley, R.Harvey, P.D.Kopala, L., et al.Risperidone and haloperidol in first-episode psychosis:a long-term randomized trial. Am J Psychiatry 2005; 162: 947953CrossRefGoogle ScholarPubMed
Weiden, P.J.Switching in the era of atypical antipsychotics. An updated review. Postgrad Med 2006; Spec N°2744Google Scholar
Submit a response

Comments

No Comments have been published for this article.